Melero, Ignacio
Molina, Carmen
Eguizabal, Cristina
Alvarez, Maite http://orcid.org/0000-0002-5969-9181
Funding for this research was provided by:
Fundación Científica Asociación Española Contra el Cáncer (INVES19041ALVA)
"la Caixa" Foundation (HR21-0083)
American Association for Cancer Research (Partners of Choice Network AstraZeneca)
Fundació la Marató de TV3 (488/C/2019)
Article History
Received: 20 February 2024
Revised: 28 February 2024
Accepted: 1 March 2024
First Online: 9 March 2024
Competing interests
: CM and CE declare no competing interests. IM reports receiving commercial research grants from AstraZeneca, BMS, Highlight Therapeutics, Alligator, Pfizer Genmab and Roche; has received speakers bureau honoraria from MSD; and is a consultant or advisory board member for BMS, Roche, AstraZeneca, Genmab, Pharmamar, F-Star, Bioncotech, Bayer, Numab, Pieris, Gossamer, Alligator and Merck Serono. MA reports receiving commercial research grants from Highlight Therapeutics and Pharmamar.